Number of the records: 1
Therapy for minimal residual tumour disease: beta-galactosylceramide inhibits growth of recurrent HPV16-associated neoplasms after surgery and chemotherapy
- 1.
SYSNO ASEP 0333598 Document Type J - Journal Article R&D Document Type Journal Article Subsidiary J Článek ve WOS Title Therapy for minimal residual tumour disease: beta-galactosylceramide inhibits growth of recurrent HPV16-associated neoplasms after surgery and chemotherapy Author(s) Šímová, Jana (UMG-J) RID
Indrová, Marie (UMG-J) RID
Bieblová, Jana (UMG-J)
Mikyšková, Romana (UMG-J) RID
Bubeník, Jan (UMG-J)
Reiniš, Milan (UMG-J) RIDSource Title International Journal of Cancer. - : Wiley - ISSN 0020-7136
Roč. 126, č. 12 (2010), s. 2997-3004Number of pages 2 s. Language eng - English Country DE - Germany Keywords beta-galactosylceramide ; tumour immunotherapy ; NKT cells Subject RIV EB - Genetics ; Molecular Biology R&D Projects GA301/06/0774 GA ČR - Czech Science Foundation (CSF) IAA500520807 GA AV ČR - Academy of Sciences of the Czech Republic (AV ČR) GA301/07/1410 GA ČR - Czech Science Foundation (CSF) GA301/09/1024 GA ČR - Czech Science Foundation (CSF) CEZ AV0Z50520514 - UMG-J (2005-2011) UT WOS 000277551100025 DOI 10.1002/ijc.24887 Annotation This study was focused on tumour-inhibitory effects of 12 carbon acyl chain beta-galactosylceramide (C12 beta-D-GalactosylCeramide) on the growth of HPV16-associated neoplasms transplanted in syngeneic mice. Treatment of tumour-bearing mice with beta-galactosylceramide 3-14 days after tumour cell transplantation significantly inhibited growth of the MHC class I-positive (TC-1), as well as MHC class I-deficient (TC-1/A9) HPV16-asssociated tumours. Administration of beta-galactosylceramide after surgical removal of TC-1 tumours inhibited growth of tumour recurrences. Similar results were obtained in the treatment of the tumours after chemotherapy. Beta-galactosylceramide treatment turned out to be also synergistic with immunotherapy based on administration of IL-12-producing cellular vaccines. These results suggest that beta-galactosylceramide can be effective for treatment of minimal residual tumour disease as well as an adjuvant for cancer immunotherapy. Workplace Institute of Molecular Genetics Contact Nikol Škňouřilová, nikol.sknourilova@img.cas.cz, Tel.: 241 063 217 Year of Publishing 2011
Number of the records: 1